Official EU label nameGlossary entry 27923

STIGMASTERYL SUCCINATE

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence

Markets checked

Markets with evidence

Evidence gaps

Resolved identifiers

A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.

Resolved substance identity

CAS:86674-63-7

Ingredient index records:

STIGMASTERYL SUCCINATE

Cosmetic functions: EMULSION STABILISING, SKIN CONDITIONING - EMOLLIENT

Stigmasta-5,22-dien-3-ol, Hydrogen Butanedionate

Open full local profile

1 matched or reported name

STIGMASTERYL SUCCINATE

Regulatory evidence in all 13 markets

Open each matched record for its scope, concentration, conditions, warnings and official source version.

Show rows

Swipe or scroll horizontally to see dataset coverage and next actions.

Market	Result	Dataset	Meaning / next action
European Union EU	No local match	Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026	No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain GB	No local match	Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026	No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada CA	No local match	Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025	The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.
New Zealand NZ	No local match	Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026	The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN ASEAN	No local match	Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026	Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China CN	No local match	Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025	IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan JP	No local match	Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot	The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion.
South Korea KR	No local match	Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026	Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States US	No local match	Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026	FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia AU	No local match	Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026	An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil BR	No local match	Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026	RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India IN	No local match	Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)	The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia SA	No local match	Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026	No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.

Chemical identity and properties

PubChem 2D chemical structure for CAS 86674-63-7

CAS 86674-63-7PubChem CID 71587319

Stigmasteryl succinate

IUPAC name: 4-[[(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid

Molecular formula: C33H52O4
Molecular weight: 512.8 g/mol
Exact mass: 512.38656014 Da
XLogP3: 8.6
Topological polar surface area: 63.6 Å²
Hydrogen-bond donors: 1
Hydrogen-bond acceptors: 4
Covalent units: 1
Defined stereocentres: 9

Also known as

StigmastStigmasterol hemisuccinateUNII-DF85J9S55ZDF85J9S55ZStigmasta-5,22-dien-3-ol, hydrogen butanedioate, (3beta,22E)-Stigmasta-5,22-dien-3-ol, 3-(hydrogen butanedioate), (3beta,22E)-STIGMASTA-5,22-DIEN-3-OL, HYDROGEN BUTANEDIOATE, (3.BETA.,22E)-STIGMASTA-5,22-DIEN-3-OL, 3-(HYDROGEN BUTANEDIOATE), (3.BETA.,22E)-

4 more reported names

RefChem:185766STIGMASTERYL SUCCINATE [INCI]Stigmasteryl hemisuccinate (STEMS)4-Oxo-4-{[(22E)-stigmasta-5,22-dien-3beta-yl]oxy}butanoic acid

Open full PubChem record PubChem annotations 3D structure image

External database identifiers

EPA DTXSID:DTXSID20235756

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Additional authoritative substance research

These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity

US EPA CompTox CTX APIs

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity

Continue the compliance check

1. Confirm identity

Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.

2. Review restrictions

Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.

3. Verify the formula

Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.

Screen in a formula Open standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision